PT - JOURNAL ARTICLE AU - Jonathan Silver TI - Model for evaluating cost-effectiveness of surveillance testing for SARS-CoV2 AID - 10.1101/2020.12.02.20242644 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.02.20242644 4099 - http://medrxiv.org/content/early/2020/12/04/2020.12.02.20242644.short 4100 - http://medrxiv.org/content/early/2020/12/04/2020.12.02.20242644.full AB - Testing people without symptoms for SARS-CoV-2 followed by isolation of those who test positive could mitigate the covid-19 epidemic pending arrival of an effective vaccine. Key questions for such programs are who should be tested, how often, and when should such testing stop. Answers to these questions depend on test and population characteristics. A cost-effectiveness model that provides answers depending on user-adjustable parameter values is described. Key parameters are the value ascribed to preventing a death and the reproduction number (roughly, rate of spread) at the time surveillance testing is initiated. For current rates of spread, cost-effectiveness usually requires a value per life saved greater than $100,000 and depends critically on the extent and frequency of testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB/oversight body was required for this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data is reported in the manuscript. The Analytica model program described in the manuscript is freely available from the author.